# Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days

> **NCT00989404** · PHASE1 · COMPLETED · sponsor: **GlaxoSmithKline** · enrollment: 18 (actual)

## Conditions studied

- Influenza A Virus, H1N1 Subtype

## Interventions

- **DRUG:** Zanamivir
- **DRUG:** Zanamivir
- **DRUG:** Zanamivir

## Key facts

- **NCT ID:** NCT00989404
- **Lead sponsor:** GlaxoSmithKline
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10-12
- **Primary completion:** 2009-12-07
- **Final completion:** 2009-12-07
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2017-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00989404

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00989404, "Crossover Study to Investigate the Safety, Tolerability, and Pharmacokinetics of Repeat Dose Zanamivir/Placebo Via Devices Administered Twice Daily for 5 Days". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00989404. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*